Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress

STOCKHOLM, Sweden, Nov. 21, 2013 (GLOBE NEWSWIRE) --

Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded Best Biotech Pipeline at the World Orphan Drug Congress in Geneva. The award recognises the size and range of Sobi's orphan pipeline and also the mix across designation and authorisation phases within the portfolio. The judging panel also acknowledged Sobi's long-term future as well as the company's pioneering development approach and commitment to the rare disease and orphan drug space. "We are truly honoured by this recognition", said Geoffrey McDonough, CEO at Sobi. "In our work to create a more hopeful future for patients with rare diseases we are also seeking new models for the development of orphan drugs." Sobi was also recognized as part of the DevelopAKUre Consortium, which was awarded the Best European Industry - Patient Organisation Collaboration award. DevelopAKUre is a clinical trial programme for the drug nitisinone (Orfadin®), the first potential treatment for Alkaptonuria (AKU). It is made up of 13 hospitals, a pharmaceutical company, consultancies, universities, biotech companies and national AKU patient groups. --- About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress: http://hugin.info/134557/R/1744773/587143.pdf [HUG#1744773] Source:Swedish Orphan Biovitrum AB (publ)